cjc-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
American black bears were once not considered true or "deep" hibernators, but because of discoveries about the metabolic changes that allow black bears to remain dormant for months without eating, drinking, urinating or defecating, most biologists have redefined mammalian hibernation as "specialized, seasonal reduction in metabolism concurrent with scarce food and cold weather". American black bears are now considered highly efficient hibernators. The physiology of American black bears in the wild is closely related to that of bears in captivity. Understanding the physiology of bears in the wild is vital to the bear's success in captivity. The bears enter their dens in October and November, although in the southernmost areas of their range (i.e. Florida, Mexico, the southeastern United States), only pregnant females and mothers with yearling cubs will enter hibernation. Prior to that time, they can put on up to 14 kg (30 lb) of body fat to get them through the several months during which they fast. Hibernation typically lasts 3–8 months, depending on regional climate. Hibernating bears spend their time in hollowed-out dens in tree cavities, under logs or rocks, in banks, caves, or culverts, and in shallow depressions. Although naturally-made dens are occasionally used, most dens are dug out by the bear. During their time in hibernation, an American black bear's heart rate drops from 40 to 50 beats per minute to 8 beats per minute, and the metabolic rate can drop to a quarter of the bear's (non-hibernating) basal metabolic rate.
Cardiovascular involvement may include inflammation of the aorta, aortic valve insufficiency or disturbances of the heart's electrical conduction system. Lung involvement is characterized by progressive fibrosis of the upper portion of the lung.
In 2012, 37.1% of infants under six months of age were breastfeeding exclusively, which rose to 48% in 2022. The Sustainable Development Goals target is to achieve 70% by 2030. In the United States, the rate of women beginning to breastfeed was 76% in 2009, increasing to 83% in 2015, with 58% still breastfeeding at 6 months, although only 25% were still breastfeeding exclusively. African-American women have persistently low rates of breastfeeding compared to White and Hispanic American women. In 2014, 58.1% of African-American women breastfeed in the early postpartum period, compared to 77.7% of White women and 80.6% of Hispanic women. In 2019, 84.1% of U.S women giving birth initiated breastfeeding, with 87.4%, 85.5%, 73.6%, 90.3% and 83.1% of Hispanic, White, African-American, Asian and Multiracial mothers initiating, respectively. Rates of initiation among African-American mothers varied widely by state, with lows under 53% and highs over 90%. Breastfeeding rates in different parts of China vary considerably. Rates in the United Kingdom were the lowest in the world in 2015, with only 0.5% of mothers still breastfeeding at a year, while in Germany, 23% are doing so, 56% in Brazil, and 99% in Senegal. In Australia, for children born in 2004, more than 90% were initially breastfed. In Canada, for children born in 2005–06, more than 50% were only breastfed, and more than 15% received both breastmilk and other liquids by the age of 3 months.
Sources: en.wikipedia.org
Between 1676 and 1689, Gottfried Leibniz first attempted a mathematical formulation of the kind of energy that is associated with motion (kinetic energy). Using Huygens's work on collision, Leibniz noticed that in many mechanical systems (of several masses mi, each with velocity vi),
Cherry juice is a mass-produced food product that is consumed as a beverage and used as an ingredient in various foods, processed foods and beverages. It is sometimes used as an ingredient in cherry ice cream and in cherry pie filling. It is also used as an ingredient in cherry brandy and cherry bounce. Cherry jelly has also been produced using the juice. Cherry juice concentrate is used by food manufacturers in the production of fruit juice blends. Cherry juice from the Montmorency cherry is used to produce cherry essence, which is used as a flavor concentrate by food manufacturers.
==== Antistasin binding to factor Xa ==== Antistasin contains an N- and a C-terminal domain which are similar in their amino acid sequences with ~40% identity and ~56% homology. Each of them contains a short β-sheet structure and 5 disulfide bonds. Only the N-terminal domain is necessary to inhibit Xa while the C-terminal domain does not contribute to the inhibitory properties due to differences in the 3 dimensional structure, even though the C-terminal domain has a strongly analogue pattern to the actual active site. The interaction of antistasin with FXa involves both the active site and the inactive surface of FXa. The reactive site of antistasin formed by Arg-34 and Val-35 in the N-terminal domain suits the binding site of FXa, most likely the S1 pocket. At the same time, Glu-15 located outside the reactive site of antistasin fits to positively charged residues on the surface of FXa. The multiple binding is thermodynamically advantageous and leads to sub-nanomolar inhibition (Ki = 0.3–0.6 nM).
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.